Is Carvykti’s Launch Constrained by JNJ’s Manufacturing Capacity? JNJ Q1 2022 Earnings Call Summary
On Tuesday, April 19, JNJ held their Q1 2022 earnings call (press release / presentation) highlighting Carvykti’s (cilta-cel; JNJ / Legend’s BCMA CAR-T) FDA approval and launch strategy for r/r MM. Below, Celltelligence provides highlights and insights on Carvykti from the call.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.